8-K: Autolus Exceeds 2025 Revenue, Projects Strong 2026 Growth

Autolus Therapeutics announced preliminary unaudited net product revenue for AUCATZYL in 2025, provided 2026 revenue guidance, and updated on pipeline advancements, projecting cash runway into Q4 2027.

Summary

• Preliminary unaudited net product revenue from sales of AUCATZYL was approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025.
• The company anticipates full year 2026 AUCATZYL net product revenue to be between $120 million and $135 million.
• Based on current operating plans, current and projected cash, cash equivalents, and marketable securities are expected to fund operations into the fourth quarter of 2027.
• AUCATZYL has achieved market leadership in relapsed/refractory (r/r) B-ALL, with over 60 US centers offering treatment and successful commercial launches in the UK and EU.
• Independent real-world data from the ROCCA consortium confirmed a high level of clinical activity and a favorable safety profile for AUCATZYL, consistent with prior clinical trial results.
• Pipeline advancements include positive Phase 1 data for obe-cel in pediatric r/r B-ALL (CATULUS trial, 95.5% overall response rate) and severe lupus erythematosus (CARLYSLE trial, deep B-cell depletion, no high-grade CRS/ICANS), both progressing to Phase 2.
• Initial clinical development for obe-cel in progressive multiple sclerosis (BOBCAT trial) and AUTO8 in light-chain amyloidosis (ALARIC trial) have begun, with initial data expected by the end of 2026.
• Autolus expects a shift from previously reported negative gross margin to positive gross margin in 2026, driven by increasing patient numbers and operational efficiencies in manufacturing.

Sentiment

Score: 8

Explanation: The filing presents strong preliminary financial results for AUCATZYL's first year of commercialization, exceeding expectations, and provides robust guidance for 2026. The extension of the cash runway, anticipated shift to positive gross margins, and significant advancements across a diversified pipeline, particularly in autoimmune indications with FDA alignment, indicate strong operational execution and future growth potential. While acknowledging the preliminary nature of financials and inherent risks of cell therapies, the overall outlook is highly positive.

Positives

• Preliminary unaudited net product revenue for AUCATZYL in 2025 reached approximately $75 million, which was reported as 'well above expectations'.
• Strong 2026 revenue guidance for AUCATZYL is projected at $120 million to $135 million, indicating significant anticipated growth.
• The company's cash runway is extended into Q4 2027, providing financial stability for ongoing operations and development programs.
• Successful US launch of AUCATZYL with more than 60 treatment centers activated and established reliable, high-quality product delivery with short and consistent turn-around times.
• Independent real-world data from the ROCCA consortium confirmed AUCATZYL's high level of clinical activity and favorable safety profile, consistent with prior clinical trial results.
• Successful navigation of the challenging pricing and reimbursement process with NICE in the UK, establishing cost-effectiveness and initiating commercial launch in December 2025 under routine commissioning, a first for a CAR T therapy in the UK.
• Strong initial clinical data from the Phase 1 CATULUS trial in pediatric r/r B-ALL patients demonstrated an overall response rate (ORR) of 95.5% and low rates of high-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
• Promising data from the Phase 1 CARLYSLE trial in severe refractory systemic lupus erythematosus showed deep B-cell depletion and no ICANS or high-grade CRS, supporting progression to Phase 2.
• FDA alignment on a Phase 2 trial design in lupus nephritis and a potential registrational path to approval provides a clear development pathway.
• Anticipated shift from negative to positive gross margin in 2026, based on increasing volumes and improved manufacturing plant utilization.
• Initiation of clinical development for obe-cel in progressive multiple sclerosis (BOBCAT trial) and AUTO8 in light-chain amyloidosis (ALARIC trial) expands the company's pipeline into new indications.

Negatives

• Preliminary financial information is unaudited and subject to change, with the possibility of material adjustments pending completion of audited financial statements.
• No anticipated EU sales for AUCATZYL in 2026 due to ongoing country-by-country evaluation of pricing and reimbursement decisions, indicating potential delays in broader European market access.
• AUCATZYL carries significant safety warnings, including Cytokine Release Syndrome (CRS), Neurologic Toxicities (ICANS), prolonged cytopenias, severe infections, hypogammaglobulinemia, Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS), hypersensitivity reactions, and the potential for secondary malignancies.
• Nine patients (9%) experienced fatal adverse reactions in the FELIX study, which included infections (sepsis, pneumonia, peritonitis), ascites, pulmonary embolism, acute respiratory distress syndrome, HLH/MAS, and ICANS, with five of these patients having pre-existing and ongoing neutropenia.

Risks

• Preliminary unaudited financial results are subject to change pending completion of the company's audited financial statements for the year ended December 31, 2025, and such changes could be material.
• The company or its independent registered public accounting firm may identify items that require adjustments to the preliminary amounts, which could be material.
• Risks identified in the section titled 'Risk Factors' in the company's Annual Report on Form 10-K filed with the SEC on March 20, 2025, as well as discussions of potential risks, uncertainties, and other important factors in subsequent Quarterly Reports on Form 10-Q and other SEC filings.
• **Cytokine Release Syndrome (CRS)**: Occurred in 75% of patients (3% Grade 3) receiving AUCATZYL, with a median time to onset of 8 days. Requires immediate access to medications and resuscitative equipment.
• **Neurologic Toxicities (ICANS)**: Occurred in 64% of patients (12% Grade ≥3), including fatal or life-threatening reactions, with a median time to onset of 10 days. Requires close monitoring and supportive care.
• **Prolonged Cytopenias**: Grade ≥3 cytopenias (neutropenia, thrombocytopenia) persisted beyond Day 30 in 71% of responders and beyond Day 60 in 27% of responders following AUCATZYL infusion.
• **Infections**: Severe, including life-threatening and fatal infections, occurred in 67% of patients (41% Grade ≥3) after AUCATZYL infusion. AUCATZYL should not be administered to patients with clinically significant active systemic infections.
• **Hypogammaglobulinemia**: Reported in 10% of patients (2% Grade 3) treated with AUCATZYL, requiring monitoring of immunoglobulin levels and management per institutional guidelines.
• **Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS)**: Occurred in 2% of patients, including fatal and life-threatening reactions, requiring treatment according to institutional standards.
• **Hypersensitivity Reactions**: Serious hypersensitivity reactions, including anaphylaxis, may occur due to dimethyl sulfoxide (DMSO), an excipient used in AUCATZYL.
• **Secondary Malignancies**: Patients treated with AUCATZYL may develop secondary malignancies, including T cell malignancies, requiring lifelong monitoring.

Future Outlook

Autolus projects significant growth for AUCATZYL net product revenue in 2026, anticipating $120 million to $135 million. The company expects to achieve positive gross margins in 2026 through increased manufacturing utilization and operational efficiencies. Key pipeline programs in pediatric B-ALL, lupus nephritis, progressive multiple sclerosis, and light-chain amyloidosis are advancing, with several clinical data readouts expected by the end of 2026 and full enrollment of the pediatric B-ALL trial by H1 2027. The company's current financial resources are expected to fund operations into the fourth quarter of 2027.

Management Comments

• "We had a successful launch of AUCATZYL in the US with full year sales well above expectations and more than 60 centers offering treatment. We established reliable, high-quality product delivery with short and consistent turn-around time." Dr. Christian Itin, Chief Executive Officer.
• "The real-world data confirmed a high level of clinical activity and a favorable safety profile for AUCATZYL consistent with prior clinical trial results, and we believe this positive customer experience will be a key driver for the future growth of AUCATZYL in 2026." Dr. Christian Itin, Chief Executive Officer.
• "In 2025 we reported strong initial clinical data for the Phase 1 CATULUS trial in pediatric r/r B-ALL patients and in the Phase 1 CARLYSLE trial in patients with severe lupus erythematosus. Both data sets form a compelling basis for progressing those studies in pediatric B-ALL and in lupus nephritis to Phase 2." Dr. Matthias Will, Chief Development Officer.
• "With this strong foundation of clinical data, Phase 2 studies enrolling and demonstrated commercial and manufacturing capabilities, we believe Autolus is well positioned to drive growth with obe-cel in additional and significant indications." Dr. Matthias Will, Chief Development Officer.
• "Our 2026 commercial focus for AUCATZYL is to build on the strong center presence and positive physician experience to drive top line growth, while improving margins by reducing our manufacturing costs per batch." Dr. Christian Itin, Chief Executive Officer.
• "Our development focus is on progressing our pivotal pediatric ALL CATLULUS and lupus nephritis LUMINA studies and the exploratory BOBCAT study in progressive multiple sclerosis." Dr. Christian Itin, Chief Executive Officer.

Industry Context

Autolus Therapeutics operates in the highly competitive and rapidly evolving field of T-cell therapies, particularly CAR T-cell therapies for oncology and autoimmune diseases. The successful US launch and regulatory approvals in the UK and EU for AUCATZYL position Autolus as a significant player in the adult relapsed/refractory B-ALL market, competing with established CAR T therapies. The expansion of obe-cel into autoimmune indications like lupus nephritis and progressive multiple sclerosis represents a strategic move to diversify its pipeline and address large, unmet medical needs beyond oncology, potentially opening new market segments for CAR T technology. The focus on optimizing manufacturing and improving gross margins is a common industry challenge for cell therapy companies aiming for commercial scalability and profitability.

Comparison to Industry Standards

• AUCATZYL's reported overall response rate (ORR) of 95.5% in pediatric r/r B-ALL patients from the CATULUS trial, coupled with low rates of high-grade CRS and ICANS, is highly competitive and compares favorably to existing CAR T therapies like Kymriah (tisagenlecleucel) from Novartis, which is also approved for pediatric and young adult r/r B-ALL.
• The successful navigation of NICE pricing and reimbursement in the UK for AUCATZYL, leading to routine commissioning, is a notable achievement, as market access for advanced therapies like CAR T-cells can be challenging in European healthcare systems. This sets a positive precedent for future CAR T therapies in the UK.
• AUCATZYL's unique mechanism of action, featuring a fast off-rate CD19 binder designed to minimize over-activation and reduce toxicities while increasing CAR T peak expansion and persistence, differentiates it from other CD19 CAR T therapies such as Kymriah (Novartis) and Tecartus (Kite Pharma/Gilead), which utilize different binders and co-stimulatory domains. For instance, AUCATZYL's off-rate is 9.8 seconds compared to Kymriah's 21 minutes.
• The reported safety profile of obe-cel in pediatric patients, consistent with adults, with low rates of high-grade immunotoxicities, is a key differentiator in a patient population where safety is paramount.
• The expansion of obe-cel into autoimmune diseases like lupus nephritis and progressive multiple sclerosis positions Autolus alongside other companies exploring CAR T beyond oncology, such as Novartis and Gilead, who are also investigating their CAR T platforms for autoimmune conditions. The FDA alignment on a Phase 2 trial design and potential registrational path for lupus nephritis suggests a potentially accelerated development pathway, which is a strong competitive advantage.

Stakeholder Impact

• **Shareholders**: Positive impact from strong revenue growth, extended cash runway, and pipeline advancements, potentially leading to increased share value.
• **Patients (r/r B-ALL)**: Continued access to AUCATZYL in more treatment centers, reinforced confidence in efficacy and safety from real-world data.
• **Patients (Pediatric r/r B-ALL, Lupus Nephritis, Progressive MS, AL Amyloidosis)**: Hope for new treatment options as pipeline programs advance through clinical trials.
• **Healthcare Providers**: Positive experience with AUCATZYL's product delivery and clinical profile, supporting broader adoption and prescribing.
• **Employees**: Positive outlook due to company growth, pipeline expansion, and strategic focus on manufacturing optimization and market access.

Next Steps

• Report fourth quarter and full year 2025 financial results in March 2026.
• Increase AUCATZYL commercial footprint in the US to more than 80 treatment centers.
• Continue the ongoing commercial launch of AUCATZYL in the UK.
• Continue country-by-country evaluation of pricing and reimbursement decisions for AUCATZYL in the EU.
• Explore alternate market access mechanisms in the EU in 2026.
• Progress the Phase 2 CATULUS trial in pediatric r/r B-ALL, with full enrollment expected in H1 2027.
• Progress the Phase 2 LUMINA trial in lupus nephritis.
• Progress the exploratory BOBCAT study in progressive multiple sclerosis.
• Provide a detailed update on manufacturing life cycle plans in mid-2026.
• Report initial clinical data from the BOBCAT Phase 1 trial in progressive MS by the end of 2026.
• Report initial clinical data from the ALARIC Phase 1 trial in AL amyloidosis by the end of 2026.
• Present longer-term follow-up data from the CARLYSLE trial at the ACR Annual Meeting 2026.
• Present updated real-world experience data from the ROCCA consortium in H1 2026.

Key Dates

Recommendation

The filing demonstrates exceptional commercial execution for AUCATZYL, with 2025 sales significantly exceeding expectations and robust 2026 guidance. The extension of the cash runway into Q4 2027 provides substantial financial flexibility. Furthermore, the strong clinical data from multiple pipeline programs, particularly the rapid advancement of obe-cel into Phase 2 for pediatric B-ALL and lupus nephritis with FDA alignment, de-risks future growth. The planned shift to positive gross margins in 2026 indicates improving operational efficiency and a clear path to profitability. These factors collectively point to a company with strong momentum, expanding market opportunities, and a solid financial foundation, making it a compelling 'strong buy' for long-term investors.

Keywords

Autolus Therapeutics, AUTL, AUCATZYL, obe-cel, CAR T-cell therapy, B-ALL, Lupus Nephritis, Multiple Sclerosis, Biopharmaceutical, Financial Results, Revenue Guidance, Pipeline, Clinical Trials, CARLYSLE, CATULUS, BOBCAT, ALARIC, SEC Filing, 8-K